个人简介： 

安徽医科大学研究员，博士生导师，博士毕业于墨尔本大学的The Walter and Eliza Hall Institute，2024年5月回国加入安医大一附院教育部肿瘤免疫医药基础创新中心。以第一作者在Cancer Discovery,，Cell Death and Differentiation等在内的专业杂志发表高水平论文，他引超过1400次。

研究方向：

TP53不同突变体在肿瘤发生、发展及耐药中的作用及机制以及创新疗法的研究和开发。

联系方式：

2024500014@ahmu.edu.cn

主持课题：

国家自然科学基金面上项目（no. 82472746）

代表性论文：

1. Zilu Wang, Matteo Burigotto, Sabrina Ghetti, François Vaillant, Tao Tan, Bianca D Capaldo, Michelle Palmieri, Yumiko Hirokawa, Lin Tai, Daniel S Simpson, Catherine Chang, Elizabeth Lieschke, Sarah T Diepstraten, Deeksha Kaloni, Chris Riffkin, David CS Huang, Connie S N Li Wai Suen, Alexandra L Garnham, Peter Gibbs, Jane E Visvader. Oliver M Sieber, Marco J Herold, Luca L Fava, Gemma L Kelly, Andreas Strasser. Loss-of-function but not gain-of-function properties of mutant TP53 are critical for the proliferation, survival and metastasis of a broad range of cancer cells. Cancer Discovery, 2024, 14(2):362-379

2. Zilu Wang, Huimin Hu, Luuk Heitink, Kelly Rogers, Yue You, Tao Tan Connie Li Wai Suen, Alex Garnham, Hao Chen, Elizabeth Lieschke, Sarah T. Diepstraten, Catherine Chang, Diane Moujalled, Kate Sutherland, Guillaume Lessene, Oliver M. Sieber, Jane Visvader, Gemma L. Kelly, Andreas Strasser. The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells. Cell Death and Differentiation, 2023, 30(4):1033-1046.

3. Zilu Wang, Andreas Strasser, Gemma L. Kelly. Should mutant TP53 be targeted for cancer therapy? Cell Death and Differentiation, 2022, 29(5): 911-920.